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Introductory Chapter: B-Cells
Mourad Aribi
1. Introduction
Etymologically, the “B” from B-cells, also referred to as B lymphocytes, stands
from the name of bursa of Fabricius, a lymphoid organ found only in birds, as
reported, in 1956, by Bruce Glick and Timothy Chang [1, 2], but not from the bone
marrow as it has been believed.
B-cells represent about 5–15% of circulating blood lymphocytes and are respon-
sible for the humoral immune response, as a critical component of adaptive immune
system. Their roles are not limited only to the production of antigen-specific anti-
bodies after antigen binding with high affinity via their membrane Ig but also to
antigen presentation. This allows them to interact with cells involved in cell-
mediated immunity and to produce cytokines [3] within immunological synapses
(IS) [4, 5] that they create with both CD4+ T-cells [6] and CD8+ T-cells [7] (for
review, see [8–10]).
The current chapter presents a brief overview on Igs and phases of B-cell ontog-
eny and B-lymphoid lineage markers. The end of the chapter summarizes the main
types of diseases related to B-cell abnormalities.
2. Immunoglobulins: transmembrane and secreted B-cell receptors
2.1 Structure of Igs
2.1.1 Ig chains
The most common form of Igs in the blood has a heterodimeric structure, about
approximately 150 kDa [11], with two antibody sites—paratopes—that bind to the
epitope of a specific antigen, located in the fragment antigen-binding [F(ab)]. This
structure is composed of two identical heavy (H) and two identical light (L) chains,
these being either kappa (Lκ) or lambda (Lλ). The H and L chains are associated
with each other by disulfide bridges (Figure 1).
2.1.2 Ig domains
Each chain of Igs is composed functionally of constant (H; CH, L; CL) and
variable (H; VH, L; VL) domains. The constant region of H chain is composed of
three (for IgG, IgA, IgD) or four (for IgM and IgE) constant domains, designated,
respectively, CH1, CH2, CH3, and CH4. Except for IgM and IgE, the region between
CH1 and CH2 domains is called the hinge “H” region, permitting flexibility in the
chain [12], which is longer and more flexible in IgG3 than the other IgG subclasses
[13]. Ig L chains are composed of two separate domains, each having an approxi-
mate molecular weight of 12 kDa [14]. The association of the variable domains of
the H and L chains defines the site of attachment to the antigen (Figure 1).
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Constant domains have specify effector functions such as activation of complement
or binding to FcRs [15].
Each Ig domain contains roughly 100–110 amino acids long [14, 17] and consists
of a two-layer sandwich of seven to nine antiparallel beta-strands arranged in two
beta-sheets/-barrels with a Greek topology [18].
Ig domains play well-defined roles, which depend on the location of each one. So
the CH1 domain, located within the F(ab) region, interacts with the constant domain of
L chains. The remaining CH domains (CH2-CH3 or CH2-CH4) comprise the Fc region,
which defines the isotype, classes, and subclasses of the Ig. The CH2 (CH3 for IgM and
IgE) domain allows an important role in mediating the effector functions, including
interaction with FcRs and antibody stability thanks to the presence of N-linked glycan,
which is conserved in mammalian IgGs at Asn297 as well as in homologous regions of
other antibody isotypes [19]. The importance of N-glycosylation is well-known for
IgGs, but little is known for other isotypes [20]. The CH3 domain allows dimerization
and participates in the stabilization of the binding of the heavy chains to one another
through interactions between the CH3 domains. For both IgM and IgA, the CH3
domains have short tailpieces to which the J-chain binds via disulfide bonds, whereas
the secretory component is disulfide bonded to one of the CH2 domains of the dimer.
CH3 domain of IgG binds to FcγR and of IgE to FcεRI and CD23 [15].
2.1.3 Framework and complementarity determining regions
Each Ig V domain contains three hypervariable regions, corresponding to the site
of recognition of the antigen, thus forming the paratope (complementarity deter-
mining regions, CDR1, CDR2, and CDR3). CDRs separate four highly conserved
segments with less variability, termed the framework regions and designated FR1,
FR2, FR3, and FR4 [16] (Figure 2). As for the T-cell antigen receptor (TCR), the
Figure 1.
Molecular structure of a typical Ig molecule. Ig molecules have a symmetric structure that is stabilized by
interchain disulfide bonds. The heavy chain determines the isotypes, i.e., the classes (IgM, IgG, IgA, IgD, IgE)
and subclasses (IgG1, IgG2, IgG3, IgG4, IgA1, IgA2) of Igs. Panel (A) shows a simplified schematic
representation of an antibody molecule. Panel (B) illustrates a schematic representation of the four-chain
composition and the separate domains comprising each chain. This representation is based on the X-ray
crystallography of an IgG antibody. Three globular regions form a Y. The two antigen-binding sites are at the tip
of the arms, which are attached to the trunk of the Y by a flexible hinge region [16]. Incubation of Igs with
papain (papaya proteinase I), in the presence of a reducing agent, results in the production of two monovalent
fab fragments (50 kDa each) and one intact fc fragment (about 50–70 kDa). Igs digestion by pepsin leads to the
production of one F(ab’)2 fragment and numerous smaller peptide fragments of the fc portion. CDRs,
complementarity-determining regions; CH, heavy chain constant domain; CHO, carbohydrate; CL, light chain
constant domain; fab, fragment antigen binding; fc, fragment crystallizable; H, hinge region; Ig,
immunoglobulin; VH, heavy chain variable domain; VL, light chain variable domain.
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binding specificity of the antigen is therefore determined by the loops present at
one end of VL and VH domains of Ig chains; the difference in specificity between
antibodies is therefore related to these loops [21].
2.1.4 Isotypes and subisotypes of Igs
There are five isotypes (classes) of Igs that are structurally and functionally
distinct, IgM, IgD, IgG, IgA, and IgE. The difference between the classes of Igs lies
in the constant portion of the H chains: mu (μ) determines the IgM class, gamma (γ)
determines the IgG class, alpha (α) determines the IgA class, delta (δ) determines
the IgD class, and epsilon (ε) determines the IgE class. So the DNA encoding the
constant part of an H chain contains several constant sequences. Thus, there are
four subclasses of IgG in both humans (IgG1, IgG2, IgG3, IgG4) and mice (IgG1,
IgG2a, IgG2b, and IgG3) and two subclasses of IgA (IgA1 and IgA2) in humans,
which are unequally distributed in the body fluids [22].
Figure 2.
Subdivision of the variable region of the Ig molecule. The Ig V region contains seven amino acid regions, four of
which are FRs and three of which are CDRs. The FRs are located on the tips of the Y-shaped molecule and act as
a scaffold for the CDRs. Of note, this representation shows the physical location of the VH region and the VL
region. N region between the V and D regions is called N1, and that between the D and heavy J regions is called
N2. CDR, complementarity determining region; FR, framework region; C, invariant constant domain; V,
variable domain; D, diversity domain; J, joining domain.
Key Point 1jMain features of human Ig classes and subclasses
mIg sIg Properties
Molecular formula (μ2κ2)5 or (μ2λ2)5
Subclasses None
MW 900–970 kDa
Valency 10
Structure mIgM; monomer, sIgM: pentamer
H chain typejMW μj65–70 kDa
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Key Point 1jMain features of human Ig classes and subclasses
mIg sIg Properties
Serum concentration 0.5–2 mg/mL
In vivo serum half life 5 days
Relative serum
abundance to total
immunoglobulin
6–10%
Carbohydrate
content by weight
(glycosylation)
12%
Distribution Mainly intravascular
Crosses placenta None
Function Primary antibody response
Classical complement
pathway activation
+++
Molecular formula γ2κ2 or γ2λ2
Subclasses Yes (IgG1, IgG2, IgG3, IgG4)
MW IgG1; 150 kDa, IgG2; 150 kDa, IgG3;
170 kDa, IgG4; 150 kDa
Valency 2
Structure Monomer
H chain typejMW γ1j50 kDa, γ2j50 kDa, γ3j60 kDa,
γ4j50 kDa
Serum concentration Total IgG: 10–16 mg/mL (IgG1: 9 mg/
mL; IgG2: 3 mg/mL; IgG3: 1 mg/mL;
IgG4: 0.5 mg/mL)
In vivo serum half life IgG1: 23 days; IgG2: 23 days; IgG3: 8
days; IgG4: 23 days
Relative serum
abundance to total
immunoglobulin
75–80%
Carbohydrate
content by weight
(glycosylation)
3%
Distribution Intra- and extravascular
Crosses placenta IgG1: +; IgG2: +/; IgG3: +; IgG4: +
Function Secondary antibody response
Classical complement
pathway activation
IgG1: +; IgG2: +/; IgG3: ++; IgG4:
none
Molecular formula (α2κ2)n or (α2λ2)n
Subclasses Yes (IgA1, IgA2) [in humans, serum
IgA are mostly monomers, but a small
amount of them is found in polymeric
forms (pIgA), usually dimers, linked
by disulfide bonds and by an
additional, cysteine-rich polypeptide
termed J chain (16 kDa). Serum
monomeric IgA can also be found in
most secretions. Mucosal secretory
IgAs are mostly seen as a dimer with a
secretory piece.]
4
Normal and Malignant B-cell
Key Point 1jMain features of human Ig classes and subclasses
mIg sIg Properties
MW Secretory tetramer IgA1 or IgA2: 600
kDa; serum monomer IgA1 or IgA2:
160 kDa
Valency 2, 4, 6 or 8
Structure Monomers, dimers (more common),
and trimers and tetramers (both are
rare)
H chain typejMW α1j55 kDa, α2j55 kDa
Serum concentration Total IgA : 1–4 mg/mL (IgA1: 3 mg/
mL; IgA2 : 0.5 mg/mL)
In vivo serum half life IgA1: 6 days; IgA2: 6 days
Secretion Milk and secretions (tears, saliva,
mucous, sweat, colostrum, and
secretions from the genitourinary
tract, gastrointestinal tract, prostate,
and respiratory mucosa)
Relative serum
abundance to total
immunoglobulin
13–15%
Relative serum
abundance to total
IgA
IgA1; 85%, IgA2: 15% (higher in
secretions)
Carbohydrate
content by weight
(glycosylation)
10%
Distribution Intravascular and secretions
Crosses placenta None
Function Protects mucous membranes
Classical complement
pathway activation
None
Molecular formula δ2κ2 or δ2λ2
Subclasses None
MW 180 kDa
Valency 2
Structure Monomers
H chain typejMW δj62–70 kDa
Serum concentration 0–0.4 mg/mL
In vivo serum half life 3 days
Relative serum
abundance to total
immunoglobulin
0.2%
Carbohydrate
content by weight
(glycosylation)
13%
Distribution Lymphocyte surface
Crosses placenta None
Function Somewhat unknown; while research
have demonstrated its role in
promoting immune defense related to
inflammation and tissue damage by
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2.2 Transmembrane B-cell receptor
B-cells are defined by the presence of membrane-bound Igs (mIg) that act as
specific receptors for the appropriate antigen in mature B-cell but, also as an excel-
lent marker of the B-cell line. The mIg constitutes, with other glycoprotein chains,
the B-cell antigen receptor complex (BCR). These correspond to non-covalently asso-
ciated transmembrane disulfide-linked heterodimer phosphoprotein Igα/Igβ (CD79a
and CD79b), which are encoded bymb-1 and B29 genes, and are structurally similar
to CD3γ, δ, and ε chains on T-cells and therefore involved in signal transduction of
B-cell [23] (Figure 3). The intracytosolic portion size of the heterodimer allows it to
initiate signal transduction, following the binding of the specific antigen to the mIg.
2.3 Mobility of mIgs, capping, and antigenic modulation
Igs are very mobile on the surface of B-cells. In addition, various specific
ligands cause what is called capping, i.e., a rapid redistribution of complexes on
the surface of the cell, followed by internalization of the complexes or their
release into the surrounding environment. This transient disappearance of the
mIg receptor via its binding to specific ligands, like anti-immunoglobulin
antibodies or antigens, is called antigenic modulation, which constitutes the
initial signal for B-cell activation. The modulated membrane receptor may also be
synthesized by the cell and returned to the surface when the B-cell is metabolically
active [24, 25].
Key Point 1jMain features of human Ig classes and subclasses
mIg sIg Properties
inducing the activation and
infiltration of immune cells
Classical complement
pathway activation
None
Molecular formula ε2κ2 or ε2λ2
Subclasses None
MW 190–200 kDa
Valency 2
Structure Monomers
H chain typejMW εj70–73 kDa
Serum concentration: 10–400 ng/mL
In vivo serum half life 2.5 days
Relative serum
abundance to total
immunoglobulin
0.002%
Carbohydrate
content by weight
(glycosylation)
12%
Distribution Basophils and mast cells in saliva and
nasal secretions
Crosses placenta None
Function Protects against parasites
Classical complement
pathway activation
None
mIg: membrane-bound immunoglobulin, sIg: secreted immunoglobulin (serum or secretory Ig).
6
Normal and Malignant B-cell
2.4 Transmembrane vs. secreted B-cell receptor
The only structural difference between transmembrane and secreted B-cell
receptors (soluble immunoglobulins, sIgs) is that the C-terminal region of the heavy
Figure 3.
BCR complex structure. The BCR complex is composed of a mIg non-covalently bonded to a transmembrane
disulfide-linked heterodimer phosphoprotein composed of CD79a (Igα)/CD79b (Igβ). CD, cluster of
differentiation; mIg, membrane-bound immunoglobulin.
Figure 4.
Structural difference between the C-terminus of the H chain constant region of mIgM and sIgM. mIgM and
sIgM differ simply by the COOH ends of the μ chain and therefore by mRNAs that differ at their 30 ends.
Membrane-bound IgM (membrane μ) is slightly larger than that of secreted IgM (secreted μ) [27]. The
numbers indicate the position of amino acids. N-CHO represents the position of glycosylation of asparagine
(N, Asn) (N-glycosylation site). mIgM, membrane immunoglobulin M; sIgM, secreted immunoglobulin M.
7
Introductory Chapter: B-Cells
DOI: http://dx.doi.org/10.5772/intechopen.90636
chains contains a short hydrophobic stretch which spans the lipid bilayer of the
membrane [26] (Figure 4).
sIgs play a complementary role to that of T-cells. It needs to use other
mechanisms for antigen removal. This implies that they bind other molecules,
like complement molecules, or specialized receptors, called Fc receptors (FcRs,
receptors of fragment crystallizable region), on the surface of effector cells that
they activate, including phagocyte cells (Figure 5).
Antibodies allow B-cells to provide systemic protection of the host and
immune surveillance through pathogen recognition and organization of immune
reactions. Their expression varies according to the state of differentiation of
B-cells. After activation, B-cells transform into plasma cells that secrete antibodies
of the same specificity as their membrane BCR. Secreted antibodies are
transported rapidly throughout the body by blood or lymph or secreted through
the epithelia to protect the interface between the body and its environment. IgG
antibodies also provide a mechanism by which acquired immunity can be
transmitted from the mother to the fetus or infant, thus providing acquired
immune protection during the critical period of early life. Nevertheless, some
antibodies can bind to self-structures, referred to as autoreactive antibodies,
and induce, under certain conditions, aberrant immune responses and tissue
damage [28].
Figure 5.
Human FcRs and their cell localization and immune functions. DCs, dendritic cells; FcRn, neonatal fc receptor;
FcRs, receptors of fragment crystallizable region; FDCs, follicular dendritic cells; Fl58, phenylalanine at position
158; GC, germinal center; H131, histidine at position 131; ICs, antigen-antibody immune complexes; PIgR,
polymeric immunoglobulin receptor; R131, arginine at position 131; V158, valine at position 158.
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3. B-cell ontogeny
The differentiation of B-cells from hematopoietic stem cells into pro-B, then
pre-B, then immature B-cells, and finally into mature B-cells is characterized by
several events, including (i) modification of membrane differentiation markers;
(ii) Ig gene rearrangement, which takes place at the pro-B and pre-B stages, allowing
the expression of BCR; and (iii) negative clonal selection.
3.1 B-cell ontogenesis and maturation
B-cell ontogenesis occurs in the fetal liver, then in the bone marrow, and con-
tinues throughout life. It starts from a hematopoietic stem cell and leads to the
development of a so-called “immature” B-cell with the same and unique antigenic
specificity. The immature B-cell migrates to the peripheral lymphoid organs, where
the different stages of maturation will take place, leading to the Ig-producing
plasma cells and memory B-cells [24]. Ultra-complex regulatory mechanisms are
involved during all stages of B-cell development and lead to the generation of B-cell
repertoire with a vast diversity of antigen recognition capacity.
3.1.1 Lymphoid progenitor cells and cell fate decisions
Knowing that B-cells, T-cells, and natural killer (NK) cells all develop from the
early lymphoid progenitors that originate from totipotent hematopoietic stem cells,
cell fate results from several lineage choices. The B-cell progenitors continue to
develop in the bone marrow [21].
3.1.2 Positive and negative selection and B-cell receptor reformatting
During their development, B-cell and T-cell undergo a dual process of positive
and negative selection in which cells that react with high affinity against self-
antigens are eliminated because they constitute a significant danger of triggering
autoimmune responses.
In the case of B-cells, outside the negative selection mechanisms, cell survival
depends essentially on their ability to compete for survival factors such as the B-cell
activating factor (BAFF, also known as B lymphocyte stimulator (BLyS), a subset of
the tumor necrosis factor (TNF) tumor necrosis factor ligand superfamily member
13B), which is present in the circulation and produced by resident cells within
secondary lymphoid organs [24]. Positive selection mainly corresponds to BCR
functionality test and depends on a moderate response to the self-antigen, which
stimulates cell maturation and survival. When self-reactivity exceeds a certain level,
a process so-called receptor reformatting is triggered by inducing a new cycle of
gene rearrangements, principally in the IG L chain loci (see Chapter 2). If the
receptor reformatting fails, or if the developing B-cell leaves the bone marrow and
encounters the self-antigen soon after it arrives in the spleen, this cell will be
eliminated [21].
3.1.3 Immature B-cell generation
The differentiation of hematopoietic stem cell (HSC) into immature B-cell
passes through four successive steps, which could be identified by the presence of
certain markers, corresponding to the different stages of rearrangement of Ig genes:
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a. Early pro-B-cell. These cells appear before the start of rearrangements. They
are identified by CD45R, major histocompatibility complex class II (MHC II),
and CDI9 and CD38 markers.
b. Late pro-B-cell. Variable (V), diversity (D), and joining (J) recombinations
for Ig H chain gene segments and receptor expression for interleukin-7 (IL-
7R) are induced at this stage.
c. Pre-B-cell. There is contact between adhesion molecules and, in particular,
vascular cell adhesion molecule 1 (VCAM-1/CD106), on the surface of the
stromal cells and its ligand, very late antigen-4 (VLA-4 or α4β1 integrin, a
dimer composed of CD49d (α4) and CD29 (β1)), on the surface of the pre-B-
cells. At this point, intact μH chains are produced and exported to the cell
surface in association with proteins that simulate light chains: λ5, which is
similar to a Cλ domain, and VpreB (CD179a), which has an Ig V domain-like
structure. The μ chains associated to λ5 and VpreB form a complex which,
together with Igα and Igβ proteins, can be expressed at the cell surface and
transduce signals that inhibit other rearrangements of genes encoding the H
chains but stimulate the genes encoding L chains and cell proliferation.
Moreover, expression of the CD20 marker can be detected at this stage.
d. Immature B-cell. Thanks to a productive Ig L chain genes’ rearrangement,
these cells express IgM on their surface, which triggers a phenomenon termed
feedback inhibition, which blocks any new rearrangement of the genes
encoding the L chains, thus allowing the expression of a single and unique Ig
specificity by each B-cell clone. At this point, the cells express the CD21
marker.
These stages are strictly dependent on the presence, in the fetal liver and bone
marrow, of nonlymphoid stromal cells that come into contact with the B-cell pre-
cursors and provide the input of soluble factors in the cell microenvironment that
are essential for differentiation, such as stem tell factor (SCF) and interleukin 7
(IL-7). It should be noted, moreover, that the probability of reaching productive/
efficient rearrangements of Ig genes encoding the H and L chains and obtaining an
intact Ig expressed on the cell surface (mIg/BCR) is low. So most of the time there
are nonproductive rearrangements, which leads to the deletion of the resulting B-
cells. In addition, the differentiation of B-cells also depends, according on the cell
development stage, on the presence of intracellular enzymes. Thus, the enzymes
encoded by the recombination-activating genes (RAGs), RAG-1 and RAG-2, are
active in early and late pro-B-cells and in pre-B-cells. Finally, the activity of the
enzyme terminal deoxynucleotidyl transferase (TdT), which is involved in the
addition of N-nucleotides, stops at the pre-B-cell stage.
Key Point 2jStromal cells
• Stromal cells constitute a support tissue of an organ, i.e., a connective tissue cell that allows the
multiplication of hematopoietic stem cells (HSCs) and their differentiation by creating a
microenvironment adapted to the growth and differentiation of HSCs. They are also able to
differentiate into many cell types.
• It has recently been suggested that stromal cells play a major role, not only in the functional
regulation of many tissues and organs, but also more particularly in the immune responses. Of note,
non-hematopoietic stromal cells play a key role in the development and function of the immune
10
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system, but, paradoxically, they can also promote the persistence of many cancers and various
immune-mediated diseases. The main non-hematopoietic stromal cells involved in immunity include
fibroblasts, myofibroblasts, endothelial cells, pericytes, smooth muscle cells and mesenchymal
stromal cells.
• Bone marrow stromal stem cells (BMSC) are almost all of mesenchymal origin and, therefore, are also
known as skeletal or mesenchymal stem cells. They influence the microenvironment surrounding B-
cell precursors, and thus exert local effects on their development through cytokines and chemokines.
HSCs are multipotent cells; i.e., they are able to differentiate into each of the types of blood cells. After
each division into two cells, one of them maintains the HSCs stock and the other one differentiates into one
of three types of blood cell, i.e., leukocyte, red blood cell, or platelet.
3.1.4 Transition from immature B-cell to mature B-cell
The immature B-cell leaves the bone marrow parenchyma and passes through an
endothelial barrier and enters the blood sinusoids, where they are retained, before
finally being released into the peripheral blood [29], which allows them to migrate
to the spleen where they complete their development [30]. The transition from the
immature B-cell to the mature B-cell takes place in a few days and leads, via
alternative splicing of long primary mRNA transcripts from the IG heavy (IGH)
locus [31], to the coexpression on naïve mature B-cells of membrane IgM and IgD
that share the same antigenic specificity. Only about 5% of immature B-cells will
sustainably give rise to peripheral B-cells; however, most newly formed ones dis-
appear within a few days.
3.1.4.1 Tonic BCR signal and notch activation
A so-called BCR-mediated positive signaling tonic signal and activation of Notch
pathway, more precisely of Notch2, which is induced following the interaction with
delta-like canonical Notch ligand 1 (DLL-1) expressed on splenic endothelial niches
and required for marginal zone (MZ) B-cell development [32], allow the triggering
of a first differentiation by a lineage cell choice that does not involve the antigenic
specificity.
3.1.4.2 Intensity of tonic signal and differentiation of lymphoid follicular B-cells or MZ
B-cells
a. Low tonic signal and Notch2 commitment. These will lead to differentiation
into MZ B-cells. The latter forms a ring around the follicle and has a more
complex structure in humans, also surrounded by a perifollicular zone [PFZ]
that surrounds the red pulp. It is a macrophage-rich area (MZ macrophages
[MZMs] and metallophilic macrophages [MMMs]) that will efficiently retain
antigens from the bloodstream. In mice, the MZ B-cells are CD21++CD23-CD11
++CD11c++, IgM++IgD+/. In humans, it is not yet known whether MZ B-cells
are derived from the germinal center (CG), by an early exit at the IgM stage, or
are produced by a lineage choice during early B-cell differentiation.
b. Strong tonic signal, without Notch2 commitment. These lead to
differentiation of lymphoid follicular B-cells. Recall that these are structured
by specialized stromal cells and follicular dendritic cells (FDCs), which
play an important role in immune response by their ability to retain
11
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antigen–antibody complexes as well as in the selection of memory B-cells
during GC reactions (GCRs) [33]. They contain naive B-cells, and adjacent to
which are T-cell zones that form the periarteriolar lymphoid sheath (PALS).
Phenotypically, they are IgM+/-IgD++, CD21+/, and CD23+, in mice.
3.2 Phases of B-cell ontogeny: antigen-dependent and antigen-independent
B-cell ontogeny can be separated into two main phases: earlier antigen-
independent phase and later antigen-dependent phase (Figure 6). It should also be
recalled that thymus-independent (TI) antigens have the ability to stimulate B-cells
without T-cells’ help and are traditionally divided into two categories, TI-1 antigens
that can activate B-cells through coengagement of Toll-like receptors (TLR), such as
LPS or other bacterial polysaccharides, and TI-2 antigens that lead to extensive
cross-linking of the BCR, such as polymeric protein antigens or repeated structural
motifs [33]. Some antigens fall outside these and form a third category. Finally,
T-cell-independent responses should be discussed, knowing that T-cells could
intervene at different levels of B-cell development in response to TI antigens (For
review, see [34–36]).
3.2.1 Earlier antigen-independent phase
The first phase of B-cell differentiation and maturation would be antigen-
independent. It takes place in the bone marrow and results in the generation of
immature B-cells expressing pair L chains with μ chains to form cell surface mono-
meric IgM in association with transmembrane Igα and Igβ invariant chains, forming
the BCR complex, which is able to recognize and capture antigens.
3.2.2 Later antigen-dependent phase
The second phase of B-cell activation and final differentiation is dependent on self-
antigens, then on non-self-antigens within the secondary lymphoid organs (SLOs).
It results in the formation of plasma cells and antigenic specific memory B-cells.
Figure 6.
Phases of B-cell ontogeny. CLPs, common lymphoid progenitors; mIgM, membrane immunoglobulin M; DZ,
dark zone; LZ, light zone; HLA, human leucocyte antigen; GC, germinal center; CSR, class switch
recombination.
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4. B-cell markers: the main molecules of the B-lymphoid lineage
The majority of human peripheral blood B-cells express on their surface IgM and
IgD that have the same antigenic specificity. In addition, in humans, a large popu-
lation of circulating cells expresses membrane lgG or IgA (but very little IgE). In
some tissues, including intestinal mucosa, B-cells selectively express membrane
IgA. In addition to the Igα/Igβ heterodimer marker, which is part of the BCR
complex, there are also other molecules on the B-cell surface that play notable roles
in various cellular functions, especially in B-cell regulation, such as human comple-
ment receptor type 2 (CR2, C3d), designed as CD21, that regulates B-cell prolifera-
tive responses, and serving as a receptor for the C3d, C3dg, and iC3b proteins of
complement. B-cells also express receptor for complement component C3b (CR1,
CD35) as well as for Fc fragments (FcR) of certain Ig isotypes, such as IgG (FcγRII-
B1, CD32). Of note, only FcγRIIB1 and FcγRIIB2 have an immunoreceptor tyrosine-
based inhibitory motif (ITIM) sequence among the FcγR receptor family and are
therefore inhibitory FcRs; they do not induce phagocytosis and represent an
important receptor-mediated feedback circuit regulator by circulating antigen-
specific IgG [24, 37]. CR2/CD21 has also been described as a receptor for the
envelope glycoprotein gp350/220 of the Epstein–Barr virus (EBV) [38]. Other mol-
ecules are frequently used in routine practice as primary markers for identifying
human B-cells, including CD19, CD20, and CD22 markers. CD19 is expressed at all
stages of B-cell lineage, including normal plasma cells. CD20, a molecule restricted
to the B-cell population, has been shown to be implicated to form calcium channels
in cell membrane [39], and as an effective target for immunotherapy in treatment
of B-cell lymphoma, as well as in a number of autoimmune diseases, such as type 1
diabetes [40]. It occurs at the early pre-B-cell stage of development and remains
throughout all stages of B-cell maturation [41], ranging from pre-B-cells in the bone
marrow to short-lived plasmablasts [42]. CD22, a B-cell-restricted surface molecule
that regulates BCR signaling in mature B-cells [43], is an early marker and persists
at all stages of B-cell differentiation, which has allowed it to be a useful pan marker
for all mature B-cell subsets [44]. Recognized as a B-cell-specific sialic acid binding
Ig-like lectin 2 (Siglec-2; B-lymphocyte cell adhesion molecule [BL-CAM]), CD22
has been exploited as a therapeutic target for humanized anti-CD22 monoclonal
antibody to treat B-cell leukemia [45]. Both immature and mature mouse B-cells as
well as subsets of T-cells and NK cells and subset of abnormal T-cells involved in the
pathogenesis of systemic autoimmunity in MRL-Faslpr and MRL-Fasgld mice express
one of the five isoforms of the transmembrane tyrosine phosphatase CD45 (LCA)
found on lymphocytes [46], i.e., CD45R (B220, CD45RABC), which has been
known to play a major role in lymphocyte signaling and activation. Other B-cell
surface molecules allow them to cooperate with T-cells. They include essentially
MHC II antigens (DR, DP, and DQ, in humans, and IA and IE, in mice) and CD40
(a member of the TNF receptor superfamily, also expressed on B-cell precursors in
the bone marrow), which is capable of transducing extremely potent B-cell
activation signals. Mutations in the gene coding for CD40 ligand (CD40L/CD154),
predominantly expressed by activated CD4+ T-cells, lead to X-linked hyper-IgM
syndrome (HIGM1), a severe primary immune deficiency (PID) in humans,
characterized by recurrent infections, associated with very low or absent IgG, IgA,
and IgE levels, but normal or elevated serum levels of IgM [47]. B-cells can also be
identified using the inhibitory co-receptor CD72 (Lyb-2 in mice), containing an
ITIM in the cytoplasmic. CD72 specifically recognizes the RNA-containing
endogenous TLR7 ligand Sm/ribonucleoprotein (RNP) by C-type lectin-like domain
(CTLD) located in its extracellular region and specifically inhibits B-cell responses
to Sm/RNP by recruiting SH2 domain-containing phosphatase 1 (SHP-1) to the
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phosphorylated ITIM [48]. It has been reported to have a role in the regulation of
systemic lupus erythematosus (SLE) development [49]. Its specific ligand is CD5
[50], which is usually expressed on most T-cells, but also on a subset of mature
B-cells [51] and CD5+ B1 cells, which emerge early in development and play a major
role in autoimmunity [52]. Other markers, including CD10 and CD23, are fond at
some stages of B-cell differentiation. CD10, a neutral endopeptidase, also referred
to as common acute lymphoid leukemia antigen (CALLA), enkephalinase, and
neprilysin, is expressed in early B-cell immature stages in bone marrow, but also in
certain stages of immunopoiesis and is also present on antigen-activated cells in GC,
in humans [53]. Defined initially as the low-affinity receptor for IgE (FcεRII) and as
EBV cell surface (EBVCS) activation antigen or BLAST-2, CD23 exists in two
distinct protein isoforms, CD23α (FcεRIIa), which is constitutively expressed only
in normal B-cells and B-cell lines, and CD23β (FcεRIIb), which is an inducible
molecule detectable on various cells [54], including most mature B-cells, follicular
mantle (FM) B-cells, T-cell subsets (at low levels), NK cells, platelets, FDCs,
monocytes, eosinophils, Langerhans cells, etc. CD23, a 45 kD type II transmem-
brane glycoprotein, can be cleaved and found in plasma as a freely soluble receptor
(sCD23). In contrast to cross-linking of FcεRI that leads to degranulation of mast
cells to release vasoactive mediators, engagement of membrane-bound CD23
suppresses the production of IgE by B-cells. Moreover, CD23 participates in
many regulatory processes, including cytokine release, cell–cell contact, and
Figure 7.
BCR signaling. As mentioned above, the final activation of mature B-cell occurs in the SLOs, where they migrate
through the blood. Within the SLOs, they receive a constant supply of antigen through the circulating lymph.
The activation of B-cell is initiated after binding of an appropriate antigen to its BCR, leading to
phosphorylation of the non-covalently associated Igα/Igβ transmembrane (CD79a and CD79b). The signaling
mechanisms triggered during the B-cell activation can be summarized in four main steps: (i) antigen binding
and starting signaling cascade, (ii) phosphorylation of Igα/Igβ ITAM, (iii) signalosome complex formation,
and (iii) signalosome activation. Akt, protein kinase B/PKB; BCR, B-cell antigen receptor; BLNK, B-cell
linker; Btk, Bruton’s protein tyrosine kinase/non-receptor kinase; CD, cluster of differentiation; ERK,
extracellular signal-regulated kinase; Fyn, proto-oncogene tyrosine-protein kinase Fyn/non-receptor Fyn proto-
oncogene; Grb2, growth factor receptor-bound protein 2; ITAM, immunoreceptor tyrosine-based activation
motifs; JNK, c-Jun N-terminal kinase; Lyn, Lck/yes novel tyrosine kinase; mIg, membrane-bound immunoglobulin;
NF-κB, nuclear factor kappa-light-chain-enhancer of activated B-cells; PI3K, phosphoinositide-3 kinase; PIP2,
phosphatidylinositol-4,5-bisphosphate; PIP3, phosphatidylinositol-3,4,5-trisphosphate; PLCy2, phospholipase
C-γ2; PKCβ, protein kinase C β; SLOs, secondary lymphoid organs; SFKs, Src-family kinase/Src-protein-
tyrosine kinase or Src family tyrosine kinase; Src, proto-oncogene tyrosine-protein kinase c-Src (cellular Src
kinase); Syk, spleen tyrosine kinase/non-receptor tyrosine kinases; Vav, proteins acting as guanine nucleotide
exchange factors (GEFs) for small G proteins of the rho family.
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receptor-mediated positive and negative feedback circuits, either as a membrane-
bound glycoprotein or as sCD23 [55]. Finally, a new type of immune cell, so-called
X lymphocyte, that is a dual expresser (DE) of TCR and BCR and key lineage
markers of both B- and T-cells, has just recently been discovered in patients with
type 1 diabetes (For review see [56]).
5. Normal mature B-cell activation and signaling mechanisms
Antigen binding to mIg induces the BCR aggregation, which leads to the rapid
transmembrane disulfide-linked heterodimer phosphoprotein Igα (CD79a)/Igβ
(CD79b) ITAM phosphorylation through recruitment of Syk and SFKs (Fyn, Lyn).
This process begins with the formation of a “signalosome” [57]. The signalosome
activation leads to three main pathways [58], including Btk, PLC-γ2, and PI3K. BCR
can transactivate the B-cell co-receptor CD19, which forms, on B-cell surface, a
tetrameric co-receptor complex with CD21 and CD81 (target of anti-proliferative
antibody 1 (TAPA-1), a tetraspanin family member tetraspanin 1 (Tspan1, NET-1),
and Leu13 (CD225)) [59]. CD19 can also be BCR-independently activated but lacks
intrinsic or associated tyrosine kinase activity [60]. As CD19 has a long cytoplasmic
domain, it binds and amplifies the function of the SFKs and recruits a heterodimer
p85/p110 class IA PI3K concurrently, which phosphorylates a membrane phospho-
lipid, PIP2, leading to the production of a second messenger PIP3 [61], as well as
promoting Btk and Akt, and a serine/threonine, kinase phosphorylation in
B-cell [62] (Figure 7).
Figure 8.
Main types of diseases related to B-cell abnormalities. AID, activation-induced cytidine deaminase; Btk,
Bruton’s tyrosine kinase; HIGM1, X-linked hyper-IgM syndrome type 1; CD40L, CD40 ligand (CD154);
CSR, class switch recombination; GCs, germinal centers; Ig H, immunoglobulin heavy chain; BAFF, B-cell
activating factor also known as B-lymphocyte stimulator (BLyS) or tumor necrosis factor (TNF) ligand
superfamily member 13B (TNF-like molecule BAFF); BCL-2, B-cell lymphoma 2; EBV, Epstein–barr virus;
CVID, common variable immunodeficiency; IVIg, intravenous immunoglobulin; SCID, severe combined
immunodeficiency; SHM, somatic hypermutation; SLOs, secondary lymphoid organs; TACI, transmembrane
activator and calcium modulator and cytophilin ligand interactor; XLA, X-linked agammaglobulinemia
(Bruton’s agammaglobulinemia); HIGM2, hyper-IgM syndrome type 2 (autosomal recessive).
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6. B-cell and pathologies
B-cells are threatened by various pathologies, including (i) immune deficiency,
which results from a disruption in their homeostasis due to mutations or deletions,
abnormalities in mechanisms of gene repair, Ig class generation, Ig affinity modu-
lation, etc.; (ii) autoimmune disorders, in which potentially dangerous self-reactive
clone B-cells escape from mechanisms of tolerance; (iii) cancerous tumors, which
result from a disorder in the succession of phases of proliferation and cell death or in
the processes of generation of cell diversity; and (iv) allergies that are particularly
related to regulatory abnormalities involving Br1 (IL-10+), Br3 (TGF-β+), and reg-
ulatory B-cells (Breg, Foxp3+) [52]. The main B-cell-associated diseases are illus-
trated in Figure 8.
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